A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab

Summary

This is an exploratory, prospective, multicenter, open-label, single-arm, interventional, Phase IIb study designed to explore the associations over time between clinical assessments, multimodal imaging assessments, aqueous humor (AH) biomarker patterns, and genetic polymorphisms in participants with diabetic macular edema (DME) who are treated with faricimab.

Timeline

Start

2020-11-25

Primary completion

2022-12-22

Completion

2022-12-22

Publications

• Results Schlottmann PG, Fawzi AA, Amador M, Dieckmann A, Gibson K, Glittenberg C, Jhaveri C, Kotak A, Mar F, Neubert A, Sheth VS, Souverain A, Titz B, Vazquez-Lombardi C, Wykoff CC, Ziemssen F, Vujosevic S. Aqueous Humor Biomarkers, Efficacy, and Safety in Patients with Naive Diabetic Macular Edema Treated with Faricimab: The ALTIMETER Study. Ophthalmol Sci. 2026 Feb 26;6(5):101129. doi: 10.1016/j.xops.2026.101129. eCollection 2026 May.

Drugs

Indications